Navegando por Assunto "Ciclosporina"

Agora exibindo 1 - 2 de 2

Acesso aberto (Open Access)
Ação da ciclosporina A na via de ativação do fator de crescimento de nervo (NGF) em células neurais do SNP
(Universidade Federal do Pará, 2016-08-26) JESUS, Jessica Batista de; SENA, Chubert Bernardo Castro de; http://lattes.cnpq.br/8620752020290438; NASCIMENTO, José Luiz Martins do; http://lattes.cnpq.br/7216249286784978
A is an immunosuppressive drug with known action on T cells of the immune system used in organ transplantation and autoimmune diseases. In the nervous system, cyclosporin A acts by inhibiting the action of Calcineurin, an important second messenger from pathway of signal transduction Nerve Growth Factor (NGF), resulting in hyperphosphorylation of the nuclear factor of activated T cells (NFAT), and downregulation of NGF, TrkA and other factors that participating in this pathway. The NFAT1-4 family are dependent isoforms of calcineurin, while NFAT5 isoform is independent. It has been demonstrated the neuroprotective role of Cyclosporin A via calcineurin dependent or independent. In this study, we evaluate the action of Cyclosporine A in the PNS system, that could be associated with levels of NGF, TrkA and an independent of calcineurin transcription factor (NFAT5) that interplay the plasticity of neuronal cells derived from Dorsal root ganglia (DRG) maintained in cultures. We use E10 DRG cultures supplemented with medium conditioned E9 Retinal treated with Cyclosporin A for 48 and 72 hours. Cultures enriched neurons were confirmed by calcium imaging method. The action of Cyclosporine A in the neuritogenesis was assessed by bright field microscopy, expression of NGF, TrkA and NFAT5 was performed by RT-PCR, intracellular accumulation of NGF was evaluated by immunofluorescence and the presence of TrkA in neurons. The viability test of the cultures treated or not with the concentrations of 1-40μM Cyclosporine A was performed by MTT method. The results show an increase of NGF levels in mixed cultures, and TrkA receptor and NFAT5 in cultures enriched in neurons following treatment with cyclosporine A. Given the importance of NGF pathway in the development and maintenance of the SNP, the use of Cyclosporin A have activity in the peripheral nervous system cells, which might be used in the clinic with new target for new therapies.
Acesso aberto (Open Access)
Ciclosporina A no eritema nodoso hansênico com manifestações sistêmicas: avaliação clínica, laboratorial e histopatológica
(Universidade Federal do Pará, 2003-01-28) AZEVEDO, Maria do Socorro Marques; BRITO, Arival Cardoso de; http://lattes.cnpq.br/0563291980190339
The ENL is a severe and acute interference that attacks patients of lepromatous and borderline lepromatous leprosy forms from Ridley and Jopling classification. In this study, the immunomodulator drug cyclosporine A was used to evaluate its effectiveness in ENL reaction, whose treatment is based on the use of drugs as thalidomide that has several restrictions and that induce dependence among other damages. Ten ENL patients with systemic manifestations and more than two reactions episodes were chosen. These patients had taken high doses of corticosteroids during years and eight of they, took thalidomide more than three times too. All patients were followed clinically for 90 days and took 3-5 mg/kg/daily, besides they accomplish laboratory exams in the zero day, 15 th and 60 th of use cyclosporine A and made also hystopathologic exams (before and 60 days after cyclosporine A). It was requesting the next laboratory exams: blood-count; leuko-count; TGO; TGP; urea and creatinine. Among laboratory exams changes, there was leucocytosis in 70% of patients that was reduced until the end of follow up in the same percentage. Biochemical exams didn't show significance disturb, except for the increase of TGO in one patient and of TGP in another, besides two cases who showed increase of urea and creatinine, but later on, they were better without any additional assistance. In 40 % of patients, the first's hystopathologic exams, alterations were represented for granulomatosis dermatitis and in 30% of sick ones, for nodular dermatitis. In second exams, there was change to superficial and deep infiltration in the blood vessel walls, in 50 % of cases; septal panniculitis in 20 %. It denotes histological improvement verified in the first fifteen days of therapy. The cyclosporine A action was specially useful in systemic symptoms, except in the cases who had neuritis. Then, cyclosporine A can be an alternative for clinical improvement to leprosy reaction type II.